Presseinformationen weltweit an Journalisten und Leser verbreiten
Ewopharma AG and Dr. Falk Pharma GmbH are extending their distribution partnership of more than 27 years – for many more to come. Under the renewed distribution agreement, Ewopharma continues to manage market access and the targeted promotion of Dr. Mehr
Ewopharma is pleased to report that sugemalimab, licensed from partner CStone Pharmaceuticals, has received a I, A recommendation in the European Society for Medical Oncology (ESMO) Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline. This recommendation supports sugemalimab for Mehr
Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a new indication for sugemalimab as monotherapy for adult patients with Mehr
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key categories of interventional cardiovascular solutions: Drug-Eluting Stents – The DES Mehr
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical and consumer health products with a focus on the prevention Mehr
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights Mehr
Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, medical devices, and cosmetics. As part of a succession solution, Mehr
Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewopharma will be the new market authorisation holder for the drug and assuming all responsibilities of the former distributor Bristol Myers Squibb. Amikacin Mehr
Ewopharma and Vianex S.A. are pleased to announce their new partnership for distribution of Amikacin in Switzerland. Ewopharma will be the new market authorisation holder for the drug and assuming all responsibilities of the former distributor Bristol Myers Squibb. Amikacin Mehr
Getting 60 years in 2019 Ewopharma decided for a new appearance. The adjustments that have been made are a cautious and contemporary development – an evolution not a revolution. The new corporate design coincides with Ewopharma’s expanding role as the trusted Mehr